Safe and effective variability-a criterion for dose individualization.

BACKGROUND: : A primary goal of clinical pharmacology is to understand the factors that determine the dose-effect relationship and to use this knowledge to individualize drug dose. METHODS: : A principle-based criterion is proposed for deciding among alternative individualization methods. RESULTS: : Safe and effective variability defines the maximum acceptable population variability in drug concentration around the population average. CONCLUSIONS: : A decision on whether patient covariates alone are sufficient, or whether therapeutic drug monitoring in combination with target concentration intervention is needed, can be made by comparing the remaining population variability after a particular dosing method with the safe and effective variability.

SAFE Spotlight, March/April 2009. (this issue mislabeled 2008)

Bimonthly news for substance abuse prevention coalitions.

SAFE Spotlight, May/June 2009.

Bimonthly news for substance abuse prevention coalitions.

SAFE Spotlight, July/August 2009.

Bimonthly news for substance abuse prevention coalitions.

SAFE Spotlight, November/December 2009.

Bimonthly news for substance abuse prevention coalitions.

SAFE Spotlight, September/October 2009.

Bimonthly news for substance abuse prevention coalitions.

SAFE Spotlight, January/February 2010.

Bimonthly news for substance abuse prevention coalitions.

SAFE Spotlight, March/April 2010.

Bimonthly news for substance abuse prevention coalitions.

SAFE Spotlight, May/June 2010.

Bimonthly news for substance abuse prevention coalitions.

SAFE Spotlight, July/August 2010.

Bimonthly news for substance abuse prevention coalitions.

SAFE Spotlight, September/October 2010.

Bimonthly news for substance abuse prevention coalitions.

SAFE Spotlight, November/December 2010.

Bimonthly news for substance abuse prevention coalitions.

SAFE Spotlight, March/April 2011.

Bimonthly news for substance abuse prevention coalitions.